Call 888-647-0579 to speak with an alcohol or drug abuse counselor.

Who Answers?

Cancer Immunotherapy Shows Long-Term Promise In Lung Cancer

New, long-term results from a clinical trial presented today at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association of the Study of Lung Cancer (IASLC) show that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery — to the same extent as chemotherapy but without the side-effects of chemotherapy.

Prof. Johan Vansteenkiste from University Hospital Gasthuisberg in Belgium described the results after 44-months follow-up from a double-blind, placebo-controlled trial in 182 patients with non-small-cell lung cancer — the most common form of the disease.

After complete surgical resection of the tumor, patients were randomly assigned to receive either placebo injections or injections of MAGE-A3 ASCI administered over 27 months (five given at three-week intervals followed by eight given once every three months).

MAGE-A3 is a tumor-specific antigen, expressed in 35-50% of non-small-cell lung cancer, but not on normal cells.

“The aim is to help the body immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3,” explains Prof. Vansteenkiste. “In other words, it is a kind of treatment method that makes the body immune system specifically attack the lung cancer cells.”

After 44 months, 69 of 182 patients had experienced a recurrence of their cancer, including 57 deaths. Those given the MAGE-A3 injections had longer on average before their cancer recurred, were less likely to have any recurrence, and were less likely to die.

“Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection about 50% will relapse and die from their cancer,” says Prof. Vansteenkiste. “Postoperative chemotherapy is able to improve cure rates, but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy. This is why the signal from this phase II randomized study is important: the reduction in risk of postoperative cancer relapse is similar to the one obtained with postoperative chemotherapy, while the side-effects of this new strategy are minimal compared to chemotherapy.”

Most patients only experience mild reactions at the injection site and fever within 24 hours of the injection, he explained. “Therefore, it is suitable for long-term maintenance treatment and for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment.” A large Phase III trial of the therapy, named MAGRIT, is now underway.

source: http://www.esmo.org/

More Treatment & Detox Articles

English turn to booze on holiday

English holidaymakers are turning to drink on their breaks with the average adult consuming eight alcoholic drinks a day, a survey suggests. That equates to 80 drinks over the course of the average holiday, or well over 200 units of alcohol. More than a quarter said they ended up drinking three times more than normal…..

Charles Lieber, pioneer in alcoholism research

Dr. Charles S. Lieber, who overturned conventional wisdom by demonstrating that alcohol is a toxin that can damage the liver and that alcoholism is a disease that can be treated, died March 1 at his home in Tenafly, N.J. He was 78 and had been battling stomach cancer. Before his work in the 1970s, researchers….

Why It Is Important to Seek Alcohol Withdrawal Treatment

For those suffering from severe alcoholism, the hours following the consumption of a “last drink” are often the most dangerous time period of entering recovery. Alcohol withdrawal occurs after a heavy drinker decides to quit or significantly reduce his or her alcohol intake. Alcohol withdrawal is unique in its severity, due to the ways in….

To help, or at least do no harm

Canada’s Health Minister urgently needs an education in harm reduction. Announcing his intention to shut down Insite, the supervised injection facility serving drug addicts in Vancouver’s Downtown Eastside, Tony Clement told the House of Commons health committee that “supervised injection is not medicine; it does not heal the person addicted to drugs.” Mr. Clement got….

Understanding Why Long Term Addiction Treatment is Recommended

Research suggests that people who attend long term addiction treatment are more likely to succeed in their recovery and to have a reduced chance of relapse following treatment. According to the National Institute on Drug Abuse, “treatment approaches and individual programs continue to evolve and diversify, and many programs today do not fit neatly into….